|
Title
|
Publication Date
|
Price
|
Relevance
|
|
Global Pharmaceutical Product Lifecycle Management Forecast 2006-2012 (Interactive Model)
|
Jul 2007 |
£9,485 |
100% |
|
Global Pharmaceutical Market Forecast to 2012
|
Feb 2011 |
£1,140 |
97% |
|
Pharmaceutical Product Lifecycle Management Forecast in APAC 2006-2012 (Databook)
|
Jul 2007 |
£725 |
97% |
|
Pharmaceutical Product Lifecycle Management Forecast in North America 2006-2012 (Databook)
|
Jul 2007 |
£725 |
96% |
|
Pharmaceutical Product Lifecycle Management Forecast in Western Europe 2006-2012 (Databook)
|
Jul 2007 |
£725 |
96% |
Sustainability in the Global Pharmaceutical Industry 2011–2012
Market Trends and Opportunities, Profitability and Budget Forecasts, Pharmaceutical Industry Procurement and Marketing Initiatives
|
Nov 2011 |
£1,265 |
95% |
Psychopharmacotherapy Market Insights
Obstacles & Opportunities in Mood Disorders & Cognitive Impairment, 2005-2012
|
Nov 2005 |
£795 |
95% |
|
Middle East and Africa Pharma Sector Forecast to 2012
|
Apr 2011 |
£760 |
95% |
|
Global Ophthalmic Market Analysis & Forecasts to 2012
|
Apr 2007 |
£1,499 |
94% |
Zimbabwe Pharmaceuticals and Healthcare Report Q1
2012
|
Dec 2011 |
£330 |
94% |
|
Pharmaceutical Markets in India
|
Apr 2009 |
£820 |
94% |
Canada Pharmaceuticals and Healthcare Report Q1
2012
|
Dec 2011 |
£330 |
94% |
Germany Pharmaceuticals and Healthcare Report Q1
2012
|
Dec 2011 |
£330 |
94% |
|
Therapeutic/Diagnostic Devices for Neurological Disorders
|
Jan 2007 |
£2,760 |
94% |
|
Streamlining Information in the Pharmaceutical Industry with PLM (Review Report)
|
Aug 2007 |
£2,145 |
94% |
Global Image Dermatology Drug Market, 2005-2012, The
High-Growth Opportunities in Aesthetic Medicine
|
Nov 2005 |
£795 |
93% |
Hungary Pharmaceuticals and Healthcare Report Q1
2012
|
Nov 2011 |
£330 |
93% |
Latvia Pharmaceuticals and Healthcare Report Q1
2012
|
Nov 2011 |
£330 |
93% |
Morocco Pharmaceuticals and Healthcare Report Q1
2012
|
Jan 2012 |
£330 |
93% |
Peru Pharmaceuticals and Healthcare Report Q1
2012
|
Jan 2012 |
£330 |
93% |
Indonesia Pharmaceuticals and Healthcare Report Q1
2012
|
Dec 2011 |
£330 |
93% |
Kazakhstan Pharmaceuticals and Healthcare Report Q1
2012
|
Dec 2011 |
£330 |
93% |
Israel Pharmaceuticals and Healthcare Report Q1
2012
|
Dec 2011 |
£330 |
93% |
Turkey Pharmaceuticals and Healthcare Report Q1
2012
|
Nov 2011 |
£330 |
93% |
Chile Pharmaceuticals and Healthcare Report Q1
2012
|
Jan 2012 |
£330 |
93% |
Moldova Pharmaceuticals and Healthcare Report Q1
2012
|
Jan 2012 |
£330 |
93% |
|
Russian Pharma Sector Analysis
|
Aug 2008 |
£350 |
93% |
Sweden Pharmaceuticals and Healthcare Report Q1
2012
|
Nov 2011 |
£330 |
92% |
Switzerland Pharmaceuticals and Healthcare Report Q1
2012
|
Jan 2012 |
£330 |
92% |
Estonia Pharmaceuticals and Healthcare Report Q1
2012
|
Nov 2011 |
£330 |
91% |
